Vincent Mooser

Home / Investigators  / Vincent Mooser

Vincent Mooser

Canada Excellence Research Chair in Genomic Medicine
Professor, Department of Human Genetics

Email: vincent.mooser@mcgill.ca
Phone: (514) 398-7872

740 Dr Penfield Ave, Room 7104
Montréal, Québec, Canada, H3A 1A4


Since August 1st, 2019, Vincent Mooser MD is the holder of the Canada Excellence Research Chair in Genomic Medicine at McGill University in Montreal. His Chair is entitled : “From Genes to Next Generation Therapies”.

Vincent Mooser combines a unique blend of broad academic and industry experience covering 
internal medicine, laboratory medicine, pharmaceutical sciences and genomic / precision medicine. He is board certified in internal medicine. After an extensive training in clinical pharmacology (Lausanne), experimental pharmacology (University of Melbourne) and molecular genetics of lipid disorders (UT Southwestern, Dallas TX), he was granted a six-year research professorship award from the Swiss National Science Foundation to study the effect of environmental and genetic contributors to lipid disorders and coronary artery disease. 

In 2002, Vincent Mooser joined GSK R&D in Philadelphia to lead the effort in genetics of cardiovascular diseases. In this position, he co-designed and co-run with Prof Gérard Waeber the CoLaus (Cohorte Lausannoise) population-based cohort. He subsequently run roles of increasing responsibility (vice-president in charge of applied genetics and head of genetics for rare diseases) in GSK before returning to academia in Lausanne in 2011.

In CHUV Lausanne, he chaired for 6 years the Laboratory Department, which is the umbrella organization for the diagnostic labs in this University Hospital, with 600 collaborators. He was also elected for 3 years Vice-Dean for Clinical Research at Lausanne University Faculty of Biology and Medicine. In these capacities, he designed, obtained funding and implemented the foundation for genomic medicine at CHUV/UNIL, with the creation of the Lausanne Institutional Biobank. He subsequently focused his activities on clinical chemistry and biomarker development as a complement to genomic medicine.

Before joining McGill, Vincent Mooser was a Board member of the Swiss Academy for Medical Sciences, a member of the Analysis Group at the Federal Office of Public Health, a member of the Executive Committee of the Swiss Personalized Network, and the chairman of the Board for the Swiss Biobanking Platform. Vincent Mooser has recently been named as Adjunct Professor at the University of Bern. He contributed to 200+ peer-reviewed publications.

Research Interests

Vincent Mooser has been passionate about the use of genetics and genomics to support drug discovery and development for the past 25 years. The CERC he presently chairs has as a mission to use cutting-edge genomics and genetics to support the discovery and development of novel therapeutics. More specifically, he plans to focus on identification and validation of new targets, and on performing, in collaboration with clinical trial centers in the McGill-affiliated hospitals, a new generation of proof-of-concept trials enrolling primarily highly genetically selected participants. The approach he develops is disease and therapy-area agnostic. It takes advantage of the informativeness of naturally occurring functional variants in the human genome and capitalizes on the strengths of the McGill ecosystem, new IT, sequencing and AI as well as functional genomics technologies and highly informative clinical trials.

Recent Publications

  • Devaux, Y, Zhang, L, Lumley, AI, Karaduzovic-Hadziabdic, K, Mooser, V, Rousseau, S et al.. Development of a long noncoding RNA-based machine learning model to predict COVID-19 in-hospital mortality. Nat Commun. 2024;15 (1):4259. doi: 10.1038/s41467-024-47557-1. PubMed PMID:38769334 PubMed Central PMC11106268.
  • Bhérer, C, Eveleigh, R, Trajanoska, K, St-Cyr, J, Paccard, A, Nadukkalam Ravindran, P et al.. A cost-effective sequencing method for genetic studies combining high-depth whole exome and low-depth whole genome. NPJ Genom Med. 2024;9 (1):8. doi: 10.1038/s41525-024-00390-3. PubMed PMID:38326393 PubMed Central PMC10850497.
  • COVID-19 Host Genetics Initiative. A second update on mapping the human genetic architecture of COVID-19. Nature. 2023;621 (7977):E7-E26. doi: 10.1038/s41586-023-06355-3. PubMed PMID:37674002 PubMed Central PMC10482689.
  • Trajanoska, K, Bhérer, C, Taliun, D, Zhou, S, Richards, JB, Mooser, V et al.. From target discovery to clinical drug development with human genetics. Nature. 2023;620 (7975):737-745. doi: 10.1038/s41586-023-06388-8. PubMed PMID:37612393 .
  • Su, CY, Zhou, S, Gonzalez-Kozlova, E, Butler-Laporte, G, Brunet-Ratnasingham, E, Nakanishi, T et al.. Circulating proteins to predict COVID-19 severity. Sci Rep. 2023;13 (1):6236. doi: 10.1038/s41598-023-31850-y. PubMed PMID:37069249 PubMed Central PMC10107586.
  • Yoshiji, S, Butler-Laporte, G, Lu, T, Willett, JDS, Su, CY, Nakanishi, T et al.. Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab. 2023;5 (2):248-264. doi: 10.1038/s42255-023-00742-w. PubMed PMID:36805566 PubMed Central PMC9940690.
  • Butler-Laporte, G, Gonzalez-Kozlova, E, Su, CY, Zhou, S, Nakanishi, T, Brunet-Ratnasingham, E et al.. Correction: The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals. Clin Proteomics. 2022;19 (1):40. doi: 10.1186/s12014-022-09378-6. PubMed PMID:36376796 PubMed Central PMC9663286.
  • Butler-Laporte, G, Povysil, G, Kosmicki, JA, Cirulli, ET, Drivas, T, Furini, S et al.. Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative. PLoS Genet. 2022;18 (11):e1010367. doi: 10.1371/journal.pgen.1010367. PubMed PMID:36327219 PubMed Central PMC9632827.
  • Butler-Laporte, G, Gonzalez-Kozlova, E, Su, CY, Zhou, S, Nakanishi, T, Brunet-Ratnasingham, E et al.. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals. Clin Proteomics. 2022;19 (1):34. doi: 10.1186/s12014-022-09371-z. PubMed PMID:36171541 PubMed Central PMC9516500.
  • COVID-19 Host Genetics Initiative. A first update on mapping the human genetic architecture of COVID-19. Nature. 2022;608 (7921):E1-E10. doi: 10.1038/s41586-022-04826-7. PubMed PMID:35922517 PubMed Central PMC9352569.
Search PubMed